69 състояние (ривастигмин и метаболит NAP226- 90) и телесното тегло при пациенти с Алцхаймерова деменция.
A relationship between active substance exposure at steady state (rivastigmine and metabolite NAP226-90) and bodyweight was observed in Alzheimer’ s dementia patients.